ADMA Biologics, Inc.
ADMAStock
$8.81−52.52%52W
Market Cap$2.06B
P/E13.99x
Div yield—
Beta0.79
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-60.31%
Price vs S&P 500 (4W)4.75%
VGM Score48.61
Market Capitalization$2.06B
P/E Ratio (Annual)13.99x
Earnings Surprise History
Q1 260.19est. 0.20
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ADMAADMA Biologics, Inc. | C | C | D | $8.81 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
ADMA Biologics manufactures and markets plasma-derived immunoglobulin (IG) and intravenous immunoglobulin (IVIG) products for immunodeficient patients and those at risk for infectious diseases. The company operates through ADMA BioManufacturing, its primary revenue source, and Plasma Collection Centers, supplemented by laboratory and contract manufacturing services. It also sells plasma-derived intermediate fractions generated from its FDA-approved manufacturing process. The company derives substantially all revenue from the United States market.